Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Venus Remedies Ltd to sell Meropenem in Australia; ties up with Lupin Ltd-Business Standard


Monday, 19 May 2014 04:04am EDT 

Venus Remedies Ltd:Said it has received marketing authorisation for its antibiotic drug Meropenem from Australian regulator TGA and has tied up with Lupin Ltd to sell the drug there-Business Standard. 

Company Quote

205.1
3.85 +1.91%
1:24am EST